SEC Form 4 · accession 0001209191-16-126266
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A. Deignan
Officer — Chief Financial Officer
Period of report
Jun 7, 2016
Accepted (ET)
Jun 7, 2016 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 7, 2016 | C | 4,261 | — | A | 62,291 | D | |
| Common Stock | Jun 7, 2016 | X | 470 | $0.022 | A | 62,761 | D | |
| Common Stock | Jun 7, 2016 | S | 2 | $7.00 | D | 62,759 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF2 | — | Jun 7, 2016 | C | 9,375 | D | — | — | Common Stock | 4,261 | 0 | D |
| Warrant to Purchase Common Stock (right to buy)F4 | $0.022 | Jun 7, 2016 | X | 470 | D | Apr 28, 2014 | — | Common Stock | 470 | 0 | D |
Explanation of responses
- F1Represents shares received upon conversion of shares of Series B Preferred Stock.
- F2Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock automatically converted into 0.454545 shares of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
- F3On June 7, 2016, the reporting person exercised a warrant to purchase 470 shares of Issuer's common stock for $0.022 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 2 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 468 shares.
- F4This warrant would have expired upon the closing of the Issuer's initial public offering.